TuHURA Biosciences prepares to present new research on the Delta Opioid Receptor's role in immune regulation at the upcoming 68th American Society of Hematology Annual Meeting.
TuHURA announced three presentations at the 68th American Society of Hematology Annual Meeting on the Delta Opioid Receptor as a target in immune suppression. The release gives no clinical data, financial figures or guidance, so the event is unlikely to materially reprice the shares by itself.
TuHURA Biosciences will showcase three research presentations at the 68th American Society of Hematology Annual Meeting. The studies focus on the Delta Opioid Receptor as a critical target for regulating immune suppression in cancer and autoimmune conditions.
The presentations focus on the Delta Opioid Receptor (DOR) and its role in regulating genes associated with immune suppression, chemotaxis, and the proliferation of immune-suppressing cells.